TP 252

Drug Profile

TP 252

Alternative Names: Eicosapentaenoic acid free fatty acid derivative - Thetis; EPA free fatty acid derivative - Thetis; EPA-FFA derivative - Thetis

Latest Information Update: 12 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Thetis Pharmaceuticals
  • Class Antineoplastics; Eicosanoids; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Familial adenomatous polyposis

Most Recent Events

  • 06 May 2017 Pharmacodynamics and pharmacokinetics data from a preclinical study in Familial adenomatous polyposis presented at the Digestive Disease Week (DDW - 2017)
  • 27 Jan 2016 Thetis Pharmaceuticals has patent protection for TP 252 in USA
  • 19 Jan 2016 TP 252 receives Orphan Drug status for Familial adenomatous polyposis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top